Renazide
Renazide Brand names, Renazide Analogs
Renazide Brand Names Mixture
- Zylet (0.5% loteprednol etabonate + 0.3% tobramycin)
Renazide Chemical_Formula
C14H16ClN3O4S2
Renazide RX_link
No information avaliable
Renazide fda sheet
Renazide msds (material safety sheet)
Renazide Synthesis Reference
No information avaliable
Renazide Molecular Weight
389.879 g/mol
Renazide Melting Point
227-228oC
Renazide H2O Solubility
No information avaliable
Renazide State
Solid
Renazide LogP
1.048
Renazide Dosage Forms
Tablets (oral, 5mg)
Renazide Indication
Cyclothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
Renazide Pharmacology
Like other thiazides, cyclothiazide promotes water loss from the body (diuretics). It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Cyclothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic efficacy. Cyclothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate.
Renazide Absorption
No information avaliable
Renazide side effects and Toxicity
Oral LD50 in mouse is > 10000 mg/kg, and > 4000 mg/kg in rat. Signs of overdose include those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered hypokalemia may accentuate cardiac arrhythmias.
Renazide Patient Information
Renazide Organisms Affected
Humans and other mammals
